DIHYDROERGOTAMINE MESYLATE

Description

Dihydroergotamine mesylate (6190-39-2) is a full agonist at serotonin 5HT1B and 5HT1D receptors, IC50= 2 and 2.2 nM respectively1 and also at 5HT1A and 5HT1F receptors2. One of the oldest agents for treatment of migraine.3 Also acts as a potent vasoconstrictor and alpha-adrenergic antagonist.4

Chemical properties

White to Off-White Solid

The Uses of DIHYDROERGOTAMINE MESYLATE

α-Androgenic blocker with selective venoconstrictor properties. Also binds to serotonin 5HT1-receptors. Antimigraine.

The Uses of DIHYDROERGOTAMINE MESYLATE

vasoconstrictor, antimigraine

The Uses of DIHYDROERGOTAMINE MESYLATE

Agonist at vascular serotonin receptors; partial agonist at alpha-adrenergic and dopamine D2 receptors

What are the applications of Application

Dihydroergotamine Methanesulfonate Salt is a competitive serotonin antagonist and vasoconstrictor

Definition

ChEBI: The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotens on.

brand name

D.H.E. 45 (Valeant); Migranal (Valeant) .

Biological Activity

Partial α -adrenergic agonist. Partial D 2 dopaminergic receptor agonist. Competitive 5-HT antagonist.

storage

Room temperature

References

Lesage et al. (1998), Agnostic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines; J. Pharmacol., 123 1655 Silberstein (1997), The pharmacology of ergotamine and dihydroergotamine; Headache, 37 Suppl 1 S15 Silberstein and McCrory (2003), Ergotamine and dihydroergotamine: history, pharmacology, and efficacy; Headache, 43 144 Lipton (1997), Ergotamine tartrate and dihydroergotamine mesylate: safety profiles; Headache, 37 Suppl.1 S33